Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trial.

Piha-Paul SA, Call JA, Spira AI, Bartolomé J, de Miguel M, Chen X, Donatelli SS, Lakhani NJ

DOI: 10.1093/oncolo/oyaf301
Published: 2025 Oct 1
Container: The oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyaf301,
  title = {Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trial.},
  author = {Piha-Paul SA and Call JA and Spira AI and Bartolomé J and de Miguel M and Chen X and Donatelli SS and Lakhani NJ},
  year = {2025},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyaf301},
  url = {https://doi.org/10.1093/oncolo/oyaf301}
}

RIS

TY  - JOUR
TI  - Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trial.
AU  - Piha-Paul SA
AU  - Call JA
AU  - Spira AI
AU  - Bartolomé J
AU  - de Miguel M
AU  - Chen X
AU  - Donatelli SS
AU  - Lakhani NJ
PY  - 2025
JO  - The oncologist
DO  - 10.1093/oncolo/oyaf301
UR  - https://doi.org/10.1093/oncolo/oyaf301
ER  -

APA

SA, P., JA, C., AI, S., J, B., M, D. M., X, C., SS, D., & NJ, L. (2025). Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trial.. The oncologist. https://doi.org/10.1093/oncolo/oyaf301

Source records

pubmed · retrieved 2026-09-27T00:39:11.850Z
europe-pmc · retrieved 2026-09-27T00:39:11.876Z